2022 World Conference on Lung Cancer (ePosters)-EP05.01-011. Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience

EP05.01-011. Real World Outcomes of Durvalumab after Chemoradiotherapy in unresectable advanced Non-Small Cell Lung Cancer: The Mayo Clinic Experience

Back to course

Pdf Summary

A recent study conducted at Mayo Clinic examined the real-world outcomes of using the immunotherapy drug durvalumab in patients with unresectable advanced non-small cell lung cancer (NSCLC) after chemoradiotherapy. The study aimed to evaluate the effectiveness and tolerability of this treatment approach in a larger patient population.<br /><br />The results of the study showed that treatment with chemoradiation followed by one year of durvalumab consolidation was effective and well-tolerated. The progression-free survival (PFS) and overall survival (OS) rates at 12 months were comparable to those reported in the PACIFIC Trial, which established the use of durvalumab after chemoradiotherapy as the standard of care for unresectable, locally advanced NSCLC.<br /><br />The study also analyzed various factors related to patient outcomes. It found that performance status and PD-L1 expression were associated with overall survival. Patients with a performance status of 2 had an increased risk of progression and death compared to those with better performance status. Additionally, patients with higher expression of PD-L1 had a lower risk of death.<br /><br />The study reported some common adverse events associated with durvalumab treatment, including pneumonitis and various immune-related adverse events. The most common sites of disease progression after treatment were the brain, bone, and lung.<br /><br />The findings of the study provide valuable insights into the real-world outcomes of using durvalumab after chemoradiotherapy in patients with unresectable NSCLC. This real-world data complements the findings of controlled clinical trials, as it includes a broader patient population and can uncover rare side effects. The study also suggests potential hypotheses for future trials.<br /><br />Overall, the study supports the effectiveness and tolerability of durvalumab in real-world clinical settings and reinforces its status as the standard of care for patients with unresectable, locally advanced NSCLC.

Asset Subtitle

Joel Rivera Concepcion

Meta Tag

Speaker Joel Rivera Concepcion

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

Mayo Clinic

immunotherapy drug

durvalumab

non-small cell lung cancer

NSCLC

chemoradiotherapy

progression-free survival

overall survival

PACIFIC Trial

PD-L1 expression